Dr. Mark G.Kris

Top thoracic medical oncologist specializing in lung cancer and thymic carcinoma.

Book an appointment Call 646-608-3914 Get directionsClaim this page

About

Dr. Mark G. Kris, MD, is a distinguished medical oncologist internationally recognized for his leadership in thoracic oncology and his pioneering work in lung cancer treatment. He serves as the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center (MSKCC), where he has spent decades shaping the field through both clinical practice and groundbreaking research. After receiving his medical degree from Weill Cornell Medical College, Dr. Kris completed his residency in internal medicine at New York-Presbyterian Hospital and a fellowship in oncology at MSKCC. He is board-certified in internal medicine and medical oncology, and he has dedicated his career to advancing care for patients with lung cancer and other thoracic malignancies.

Why they are a top doctor

Research papers · PubMed

499

Published, peer-reviewed work, the clearest public measure of expertise in a specialty.

Cited by other doctors

103.1k

How often other doctors and researchers build on their work.

Known for

Biomarker testing

The distinction that sets them apart from other thoracic medical oncologists.

Background

Education

Medical school

Weill Cornell Medical College

Residency

Internal Medicine at New York Hospital - Memorial Sloan Kettering Cancer Center

Fellowship

Medical Oncology - Memorial Sloan Kettering Cancer Center

Board certification

Internal Medicine, Medical Oncology

Areas of focus

Lung cancer

Thymoma

Mediastinal tumors

Biomarker testing

Awards

ASCO Inaugural Humanitarian Award

IASLC Distinguished Service Recognition for Lung-Cancer Education

William & Joy Ruane Endowed Chair in Thoracic Oncology

NCCN Guidelines Panel Member (NSCLC, SCLC)

Memberships and affiliations

American Society of Clinical Oncology (ASCO)

American Association for Cancer Research (AACR)

International Association for the Study of Lung Cancer (IASLC)

National Comprehensive Cancer Network Lung-Cancer Panels

Selected publications

IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy.

Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer.

Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis.

Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives.

Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.

HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers.

Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis.

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.

Serpins promote cancer cell survival and vascular co-option in brain metastasis.

Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer.

Titles as indexed on PubMed.

Where they practice

All hospitals ›

Memorial Sloan Kettering Cancer Center

New York, NY

One of the world’s oldest and largest private cancer centers, in New York City, focused only on cancer and treating every type, including rare ones.

Trials for lung cancer

All trials ›

Combining New Treatments to Improve Care for Lung Cancer Patients

Recruiting · Phase 2/Phase 3

Tests better care for people with lung cancer. It compares it with the usual care. Open to adults across the US.

Targeting Advanced Lung Cancer with Osimertinib Alone or with Bevacizumab

Recruiting · Phase 3

Tests a medicine for lung cancer. It compares it with the usual care. Open to adults across the US.

Comparing Immunotherapy with Standard Chemotherapy for Lung Cancer After Surgery

Recruiting · Phase 3

Tests a medicine for lung cancer. It compares it with the usual care. Open to adults across the US.

Similar specialists

Dr. RielyDr. Gregory Riely

Medical OncologistMedical Oncologist · New York, NY · New York · NY

Known for contributions to the understanding of oncogene-driven lung cancers and the development of targeted therapies. Treats lung cancer and thymoma and thymic carcinoma. Works as a thoracic medical oncologist. Based in New York. Chosen on merit.

Lung cancer+1

Dr. SmithDr. Cardinale Smith

Medical OncologistMedical Oncologist · West Harrison, NY · New York · NY

Chief Medical Officer (CMO) at MSK. Treats small cell lung cancer, non-small cell lung cancer and thymoma and thymic carcinoma. Offers palliative care. Works as a thoracic medical oncologist. Based in West Harrison, New York. Chosen on merit.

Small cell lung cancer+2

Dr. RudinDr. Charles Rudin

Medical OncologistMedical Oncologist · New York, NY · New York · NY

A medical oncologist who treats lung cancer in New York, NY. Treats lung cancer. Works as a thoracic medical oncologist. Based in New York. Chosen on merit.